Medical Devices · Fremont, California, United States
n/a
Smart-Money SignalNeutral · 51/100— Insider open-market flow is flat over 90 days
Net Income-$2.8M
Price Performance
Historical data including institutional events
Company Profile
M
Michael Handley
CEO & Executive Director
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company.
Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome.
The companyâs pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications.
In addition, it offers CDMO services. The company was incorporated in 2016 and is based in San Antonio, Texas.
